Johnson & Johnson receives CE mark for new 2-week contact lens
At a glance
- $JNJ today−1.12%last $282.55
- Vs industry peers−0.73 pts6-peer median −0.39% · behind
- Since Sep 10+6.08%from the first trade after the story
- 52-week range2.7% below high$195.90 – $290.25
- Last reported profit$210.0Mquarter to Sep 27, 2026 · 10-Q
- Coverage1 this week11 in 30 days · quieter than usual
Nothing reported about Johnson & Johnson across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.
Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.
What it means
- What to watch: In healthcare, the calendar is the catalyst: trial readouts, FDA dates and pricing rules drive most of the moves.
- How the stock is trading: $JNJ -1.12% in the latest session.
- Timing: It came out pre-market, so the next session was the first that could react.
Where the stock stands
Johnson & Johnson ($JNJ) fell 1.12% to $282.55 in the latest session. Over the past month it is up 11.3%. It now sits 2.7% under the 52-week high of $290.25 and 44% above the year's low of $195.90, close to the top of its range. Its range over the year spans 48%, which is moderate.
What the filings say
In its latest report (10-Q, filed Oct 21, 2026), $JNJ earned $210.0M over the quarter to Sep 27, 2026 on revenue of $25.40B (+0.4% QoQ). Operations brought in $18.85B of cash over the nine months to Sep 27, 2026; after capital spending, free cash flow was $15.12B. It carried $37.80B of debt against $16.91B of cash on Sep 27, 2026 — net debt of $20.89B. Its most recent filings before this story: 8-K on Aug 4, 2026, 8-K on Jul 29, 2026, 8-K on Jul 28, 2026. Figures are as filed with the SEC; the $JNJ page has the full statements.
How much coverage it is getting
This story is more than a month old. Since then Wook has filed 11 newer stories on Johnson & Johnson in the last 30 days, 1 of them this week. By their wording, 18% read bullish, 55% neutral and 27% bearish.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Health Care reads calm on Wook's supply-chain scanner today, with no unusual stress in the filings and disclosures it watches.
Coming up
$JNJ earnings in 71 days — on the calendar well before this story broke.
What to watch next
The company's own filings are the primary source. Its latest SEC reports, including any filing on a material event, are on the $JNJ page, and they say what management has disclosed without a reporter in between. Reading how two or three outlets frame the same story is the quickest way to separate the facts from the angle. To run the numbers yourself, ask Wook AI above about $JNJ: its distance from the high, its last report, or how coverage has changed.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Investing.com published this on September 10, 2026. $JNJ has moved +6.08% ($266.35 to $282.55). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.
